Eloralintide 48-week phase 2 trial in obesity
263 US adults with obesity or overweight plus a comorbidity, no diabetes
Weight fell 9% (1 mg) to 20% (9 mg) versus 0.4% on placebo at 48 weeks (efficacy estimand).
Read the studyLilly's investigational weekly amylin-receptor agonist; up to 20% weight loss at 48 weeks in phase 2, now in phase 3.
Also called LY3841136, EloraTZP (when combined with tirzepatide)
Eloralintide is an injectable copy of amylin, a hormone the pancreas releases with insulin after meals to signal fullness. Eli Lilly modified it to last about two weeks in the blood and to prefer one amylin receptor subtype (AMY1) over the plain calcitonin receptor. The idea is to get amylin's appetite effect with less of the nausea that GLP-1 drugs cause. It is not approved anywhere.
In a 48-week phase 2 trial of 263 US adults with obesity, weight fell 9% on 1 mg and up to 20% on 9 mg, against 0.4% on placebo. Those numbers use the efficacy estimand, which counts people who stayed on the drug. Nausea and tiredness were the main side effects, and both climbed with dose: on a fixed 9 mg start, 43% reported fatigue. Stepping up from 3 mg to 9 mg cut nausea to 25%, against 64% on a fixed 6 mg start and 14% on placebo.
Lilly started five phase 3 trials (ENLIGHTEN) in late 2025 and early 2026, with the main obesity trial running to 2028. Lilly is also testing it on top of tirzepatide: in a phase 2b trial in type 2 diabetes, the combination produced up to 23.3% weight loss versus 14.8% on tirzepatide 15 mg alone, with more people stopping for side effects.
What it binds to, and what happens inside the body after that, step by step.
Eloralintide activates amylin receptors, which are the calcitonin receptor paired with a helper protein (RAMP). In cell assays it was 12 times more active at the human AMY1 receptor than at the bare calcitonin receptor. Amylin signaling in the brainstem produces fullness, slows stomach emptying and lowers glucagon after meals. In rats it caused less taste aversion, a lab stand-in for nausea, than cagrilintide.
Human results and animal results are kept apart below. A result in rats tells you a mechanism is plausible. It does not tell you what happens in a person.
One 48-week placebo-controlled phase 2 trial in 263 people shows large, dose-dependent weight loss, backed by two phase 1 studies and a phase 2b combination trial with tirzepatide. Phase 3 results do not exist yet, the phase 2 headline numbers use the efficacy estimand, and there is no long-term or cardiovascular safety data.
263 US adults with obesity or overweight plus a comorbidity, no diabetes
Weight fell 9% (1 mg) to 20% (9 mg) versus 0.4% on placebo at 48 weeks (efficacy estimand).
Read the study367 adults with obesity or overweight and type 2 diabetes, 48 weeks
Combination gave 13.2% to 23.3% weight loss versus 14.8% on tirzepatide 15 mg alone, 8.2% to 12.3% on eloralintide alone and 3.0% on placebo (efficacy estimand); presented at EASD 2026, not yet peer reviewed.
Read the study100 adults with obesity or overweight, 12 weeks
Weight fell 2.6% to 11.3% at 12 weeks with no dose escalation; nausea in only 8%.
Read the studyRats, monkeys, and 48 healthy adults given single doses
Single doses of 4 mg and 12 mg cut weight 2.5% and 4.4% at 4 weeks versus a 0.6% gain on placebo; half-life 310 to 366 hours.
Read the studyNo preclinical studies are listed as key studies here. The human data above carries the evidence.
These are questions the published research has not answered.
No product containing Eloralintide is approved as a medicine by the FDA.
Phase 3 ENLIGHTEN program under way: ENLIGHTEN-1 (obesity without diabetes, 1,980 people, 64 weeks), ENLIGHTEN-2 (with type 2 diabetes), ENLIGHTEN-3 (sleep apnea), ENLIGHTEN-4 (knee osteoarthritis pain) and ENLIGHTEN-6 (people still with obesity on incretin therapy). WADA: not named on the 2026 Prohibited List, but as a drug with no regulatory approval it falls under S0 (non-approved substances), banned at all times.
How much of Eloralintide is left after a single dose
Simple first-order model from the published half-life. Real clearance varies with dose, route, kidney and liver function and formulation. This is not a dosing schedule.
This table records the doses that trials and approved labels used, with the source for each row. It is a record of research, not a recommendation, and it is open to free members.
Which symptoms are expected and which mean stop and get help: side effects and red flags.
Tap a claim to see what the studies found.
Nausea was 64% on a fixed 6 mg start in phase 2. Slow escalation brought it down, but it is not nausea-free.
In the phase 2b diabetes trial, eloralintide alone gave 8.2% to 12.3% versus 14.8% for tirzepatide 15 mg. No obesity head-to-head trial exists.
Rat data showed mostly fat loss, but no human body-composition comparison has been published.
Both are long-acting amylin analogs, but cagrilintide hits amylin and calcitonin receptors broadly, while eloralintide prefers AMY1 and has about twice the half-life.
These pairings come up often. Almost none have been tested together in a trial, and the evidence note on each says so plainly.
Amylin signaling and GLP-1/GIP signaling reduce appetite through different brain pathways, so the effects add up.
EvidenceOne 48-week phase 2b trial in 367 adults with type 2 diabetes: up to 23.3% weight loss versus 14.8% for tirzepatide alone, with higher dropout. Presented at EASD 2026; not yet peer reviewed.
No public label. Trial supplies are handled under sponsor instructions that have not been published.
No public label or stability data.
One email when a trial reads out, a label changes or the FDA acts on a peptide. Free, no selling of peptides, unsubscribe any time.